Ratings BioNTech SE

Equities

BNTX

US09075V1026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
88.01 ^USD	+1.38%		+0.14%	-16.61%

Apr. 15	Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...
Apr. 15	Market outlook is uncertain, but optimism prevails

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's share price in relation to its net book value makes it look relatively cheap.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIONTECH SE	-16.61%	21.21B	B+
REGENERON PHARMACEUTICALS, INC.	+2.49%	96.73B	B+
ARGENX SE	-0.29%	21.31B	B
GENMAB A/S	-5.34%	18.79B	A-
WUXI APPTEC CO., LTD.	-42.14%	16.37B	A-
BEIGENE, LTD.	-27.40%	13.68B	B
NEUROCRINE BIOSCIENCES, INC.	+1.44%	13.44B	C+
SAREPTA THERAPEUTICS, INC.	+21.29%	10.98B	C+
LEGEND BIOTECH CORPORATION	-21.79%	8.56B	D
ASCENDIS PHARMA A/S	+12.82%	8.12B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes